STOCKHOUSE: Lattice Biologics (TSX-V: LBL) (OTCBB: BLVKF) adds biotech opportunity to Stockhouse’s Deal Room

Gaalen Engen,
April 22, 2016

Lattice Biologics (TSX-V: LBL, OTCBB: BLVKF, Forum) extended investment opportunities directly to accredited investors today when the company went live on Stockhouse’s new revolutionary Deal Room, a curated directory of finance offerings being made available through exempt market dealer, Waverley Corporate Financial Services.

Lattice is breaking new ground in the personalized/precision cancer diagnostics and advanced tissue regeneration spaces with a patent-pending technology. It develops and manufactures biological products for use in a series of clinical applications including fusion enhancement in spinal surgeries, breast reconstruction enhancement, bone regeneration, bone defect repair and sports medicine indications.

The revolutionary application of the aforementioned patent-pending technology in the arena of cancer treatment will allow physicians for the first time ever to find the optimal treatment regime and therapy specific to the patient and the patient’s tumour without having to subject the patient themselves to the traditional generalized trial and error approach. To this end, Lattice has entered into an Industry Sponsored Collaboration Agreement with the renowned Sunnybrook Research Institute, a fully-affiliated research and teaching hospital with the University of Toronto, to develop new cancer screening research methods.

Lattice’s veteran management team has an established track record, creating and building a $400 million-plus market cap company in the same market. The company has already leveraged its existing FDA-approved products, currently serving over 500 surgeons with over US$4.0 million in sales in 2015, to position Lattice for positive cash flow by the end of 2016.

The company’s $300,000 financing currently listed in Stockhouse’s Deal Room will close in tranches and involves the purchase of units for $0.30 per unit. Each unit will be made up of one common share of Lattice and one-half of one non-transferable common share purchase warrant. Each whole warrant is exercisable into an additional common share at a rate of $0.30 per share for up to 36 months from the closing date.

Gross proceeds from the financing will be used for general working capital in order to elevate production levels of the company’s current products and further strengthen Lattice’s balance sheet.

With heavy insider involvement, Lattice is tightly-held and has the ability to scale quickly in a multi-billion market. Combined with the additional blue sky potential of its cancer diagnostics breakthrough, Lattice could quite possibly find itself as a major player in separate multi-billion dollar addressable markets and shareholders may find themselves in the position to celebrate. That of course is my opinion. As always do your due diligence before making any investment decision. You can check out the basic details of Lattice’s financing here and have click-through access to Waverley where you will be able to qualify and participate in this new biotech opportunity.

–Gaalen Engen

FULL DISCLOSURE: Lattice Biologics is a Stockhouse Publishing client.


Media Contact: Melanie Battista, Public Relations, Lattice Biologics Ltd., 16701 N 90th Street, Suite #101, Scottsdale, AZ 85260, 480-563-0800 Office, |